Find in Library

<b>Background:</b> Phage therapy a promising antimicrobial strategy to address antimicrobial resistance for infections caused by the major human pathogen <i>Staphylococcus aureus</i>. Development of therapeutic phages for human use should follow pharmaceutical standards, including selection of strictly lytic bacteriophages with high therapeutic potential and optimization of their production process. <b>Results:</b> Here, we describe three novel <i>Silviavirus</i> phages active against 82% of a large collection of strains (n = 150) representative of various methicillin-susceptible and -resistant <i>S. aureus</i> clones circulating worldwide. We also investigated the optimization of the efficiency and safety of phage amplification protocols. To do so, we selected a well-characterized bacterial strain in order to (i) maximize phage production yields, reaching phage titres of 10¹¹ PFU/mL in only 4 h; and (ii) facilitate phage purity while minimizing the risk of the presence of contaminants originating from the bacterial host; i.e., secreted virulence factors or induced temperate phages. <b>Conclusions:</b> In sum, we propose a quality-by-design approach for the amplification of broad-spectrum anti-<i>S. aureus</i> phages, facilitating the subsequent steps of the manufacturing process; namely, purification and quality control.